CN117430527A - 一种2-烷基-2-氰基戊酸酯的制备方法 - Google Patents
一种2-烷基-2-氰基戊酸酯的制备方法 Download PDFInfo
- Publication number
- CN117430527A CN117430527A CN202311398742.XA CN202311398742A CN117430527A CN 117430527 A CN117430527 A CN 117430527A CN 202311398742 A CN202311398742 A CN 202311398742A CN 117430527 A CN117430527 A CN 117430527A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- catalyst
- cyanovalerate
- acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000003054 catalyst Substances 0.000 claims abstract description 22
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 15
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 7
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 claims abstract description 7
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 claims abstract description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 5
- 229940005605 valeric acid Drugs 0.000 claims abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 4
- 239000003513 alkali Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 31
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 30
- 229960000604 valproic acid Drugs 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 15
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 claims description 12
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical group [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 claims description 12
- OVBFMEVBMNZIBR-UHFFFAOYSA-N 2-methylvaleric acid Chemical compound CCCC(C)C(O)=O OVBFMEVBMNZIBR-UHFFFAOYSA-N 0.000 claims description 10
- ODPKTGAWWHZBOY-UHFFFAOYSA-N 2-propan-2-ylpentanoic acid Chemical compound CCCC(C(C)C)C(O)=O ODPKTGAWWHZBOY-UHFFFAOYSA-N 0.000 claims description 9
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 claims description 9
- HWXRWNDOEKHFTL-UHFFFAOYSA-N 2-propylhexanoic acid Chemical compound CCCCC(C(O)=O)CCC HWXRWNDOEKHFTL-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- BAZMYXGARXYAEQ-UHFFFAOYSA-N alpha-ethyl valeric acid Chemical compound CCCC(CC)C(O)=O BAZMYXGARXYAEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- IJJJSNBMFDDFBC-UHFFFAOYSA-N 2-cyanoethyl acetate Chemical compound CC(=O)OCCC#N IJJJSNBMFDDFBC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 3
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004412 Bulk moulding compound Substances 0.000 claims description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 claims description 2
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940019778 diethylene glycol diethyl ether Drugs 0.000 claims description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims description 2
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 claims description 2
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 claims description 2
- UQFSVBXCNGCBBW-UHFFFAOYSA-M tetraethylammonium iodide Chemical compound [I-].CC[N+](CC)(CC)CC UQFSVBXCNGCBBW-UHFFFAOYSA-M 0.000 claims description 2
- DDFYFBUWEBINLX-UHFFFAOYSA-M tetramethylammonium bromide Chemical compound [Br-].C[N+](C)(C)C DDFYFBUWEBINLX-UHFFFAOYSA-M 0.000 claims description 2
- RXMRGBVLCSYIBO-UHFFFAOYSA-M tetramethylazanium;iodide Chemical compound [I-].C[N+](C)(C)C RXMRGBVLCSYIBO-UHFFFAOYSA-M 0.000 claims description 2
- BGQMOFGZRJUORO-UHFFFAOYSA-M tetrapropylammonium bromide Chemical compound [Br-].CCC[N+](CCC)(CCC)CCC BGQMOFGZRJUORO-UHFFFAOYSA-M 0.000 claims description 2
- FBEVECUEMUUFKM-UHFFFAOYSA-M tetrapropylazanium;chloride Chemical compound [Cl-].CCC[N+](CCC)(CCC)CCC FBEVECUEMUUFKM-UHFFFAOYSA-M 0.000 claims description 2
- GKXDJYKZFZVASJ-UHFFFAOYSA-M tetrapropylazanium;iodide Chemical compound [I-].CCC[N+](CCC)(CCC)CCC GKXDJYKZFZVASJ-UHFFFAOYSA-M 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- 238000007171 acid catalysis Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 19
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 14
- 238000002390 rotary evaporation Methods 0.000 description 11
- 229940102566 valproate Drugs 0.000 description 11
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 9
- 229940084026 sodium valproate Drugs 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical group [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UZRGQIZTJOPZGE-UHFFFAOYSA-N 2-cyano-2-propylpentanoic acid Chemical compound CCCC(C(O)=O)(C#N)CCC UZRGQIZTJOPZGE-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- TZHBUTDMKLWZDI-UHFFFAOYSA-N 2-cyanopropan-2-yl pentanoate Chemical compound CCCCC(=O)OC(C)(C)C#N TZHBUTDMKLWZDI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NLFIMXLLXGTDME-UHFFFAOYSA-N propyl 2-cyanoacetate Chemical compound CCCOC(=O)CC#N NLFIMXLLXGTDME-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- WNZKWBYFYOMJRC-UHFFFAOYSA-N methyl 2-cyanopentanoate Chemical compound CCCC(C#N)C(=O)OC WNZKWBYFYOMJRC-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- -1 propyl 2-cyano-2-propylvalerate Chemical compound 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BAZMYXGARXYAEQ-UHFFFAOYSA-M 2-ethylpentanoate Chemical compound CCCC(CC)C([O-])=O BAZMYXGARXYAEQ-UHFFFAOYSA-M 0.000 description 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- RZBSVYZMOJXQJU-UHFFFAOYSA-N [Na].CCCO Chemical compound [Na].CCCO RZBSVYZMOJXQJU-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000000911 decarboxylating effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- GYNAUHCPFGDIOY-UHFFFAOYSA-N ethyl 2-cyano-2-methylpentanoate Chemical compound CCCC(C)(C#N)C(=O)OCC GYNAUHCPFGDIOY-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940023568 magnesium valproate Drugs 0.000 description 1
- LKLLHOIUJVEAGU-UHFFFAOYSA-L magnesium;2-propylpentanoate Chemical compound [Mg+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC LKLLHOIUJVEAGU-UHFFFAOYSA-L 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/06—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid amides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及式Ⅰ所示的2‑烷基‑2‑氰基戊酸酯的制备方法:其特征在于氰基乙酸酯与1‑氯丙烷(含2‑氯丙烷和1‑氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2‑烷基‑2‑氰基戊酸酯:R1选自苄基、C1~C5直链烷基或C3~C5支链烷基;R2选自甲基、乙基、丙基、丁基或异丙基;Ⅰ所示的2‑烷基‑2‑氰基戊酸酯在碱催化下水解制得2‑烷基‑2‑氰基戊酸(Ⅱ);式Ⅰ所示的2‑烷基‑2‑氰基戊酸酯在酸催化下水解和脱羧制得2‑烷基戊酸(Ⅲ)。
Description
技术领域
本发明涉及一种2-烷基-2-氰基戊酸酯的相转移复合催化制备方法与应用。
背景技术
丙戊酸钠由美国第三大制药企业雅培公司研制,1983年美国FDA批准上市的一种治疗癫痫的药物,随后在1995年和1996年分别获准用于治疗双相情感障碍症和预防偏头痛。丙戊酸钠主要用于癫痫治疗,可作为单药或添加治疗;可用于治疗全面性癫痫、部分性癫痫、局部癫痫发作,伴有或不伴有全面性发作。还可用于躁狂症,与双相情感障碍相关的躁狂发作。丙戊酸钠片的主要成分为丙戊酸钠,丙戊酸钠缓释片的主要成分为丙戊酸钠和丙戊酸。丙戊酸钠具有广谱的抗癫痫活性,为国内外临床抗癫痫的首选药物。
1984年李辛缘等[固液相转移催化反应合成丙戊酸类抗癫痫药物.医药工业,1984,5:4-6;李辛缘.新型抗癫痫药物—丙缬草酰胺的合成,医药工业,1981,(11):1-2]选择氰基乙酸甲酯、1-溴丙烷和固体碳酸钾,在季铵盐催化下二丙烷基化,再经水解、脱羧和成盐制备丙戊酸钠/镁或丙戊酰胺。
印度专利[IN486MU2014A 2015-09-25]选择氰基乙酸乙酯和1-溴丙烷在丙醇钠作用下,发生二丙烷基化制备2-丙基-2-氰基戊酸乙酯,后者不分离催化水解得到2-丙基-2-氰基戊酸,收率90%~94%;2-丙基-2-氰基戊酸经硫酸催化水解制备丙戊酸,收率85%~90%。制备反应如下:
英国专利[GB2068962A,1981-08-19]描述了丙戊腈经硫酸催化水解制备丙戊酸,制备反应如下:
上海青平药业有限公司[一种丙戊酸制备新方法,CN 2021103366414,2021.8.3公开;一种丙戊酸钠的制备方法,CN2021103339474,2021.8.3公开;一种制备丙戊酸的方法,CN 2021103366274,2021.7.27公开]描述了一种制备丙戊酸和丙戊酸钠的方法:以丙戊腈或2-氰基-2-丙基戊酸为原料,硫酸为催化剂,在120~160℃反应20h~40h,制得丙戊酸,收率70%~80%;其合成路线如下:
上海青平药业有限公司[一种2-R1戊酸的制备方法,ZL 202110336630.6,2021.7.23公开]描述了氰基乙酸甲酯、甲醇和1-溴丙烷在45~60℃,滴加30~40%甲醇钠甲醇溶液,反应结束后,旋蒸甲醇得到粗品,纯化得到2-氰基戊酸甲酯;2-氰基戊酸甲酯再甲基化、乙基化或异丙基化,水解和脱羧分别得到2-甲基戊酸(L)、2-乙基戊酸(B)或2-异丙基戊酸(C)[魏正华.中国医药工业杂志,2-异丙基戊酸的合成,2023,54(05):739-741]:
发明内容
本发明的目的一方面是提供化学结构式Ⅰ所示的2-烷基-2-氰基戊酸酯的制备方法:其特征在于氰基乙酸酯与1-氯丙烷(含2-氯丙烷和1-氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2-烷基-2-氰基戊酸酯:
R1选自苄基、C1~C5直链烷基或C3~C5支链烷基;R2选自甲基、乙基、丙基、丁基或异丙基;
二烷基化的催化剂由催化剂R4NX和催化剂B组成;其中R=C1~C5直链烷基,X=Cl、Br或I;R4NX选自四丁基氯化铵、四丁基溴化铵、四丁基碘化铵、四丙基氯化铵、四丙基溴化铵、四丙基碘化铵、四乙基氯化铵、四乙基溴化铵、四乙基碘化铵、四甲基氯化铵、四甲基溴化铵或四甲基碘化铵;催化剂B选自KBr或KI;
二烷基化的溶剂选自THF、DMF、DMC、DMSO、乙腈、丙腈、丁腈、1,4-二氧六环、乙二醇二甲醚、乙二醇二乙醚、二乙二醇二甲醚、二乙二醇二乙醚;
K2CO3选自100目K2CO3、150目K2CO3、200目K2CO3、250目K2CO3、300目K2CO3或350目K2CO3;
二烷基化反应温度选自60℃~120℃;反应时间选自1.0h~12h;
二烷基化催化用量选自氰基乙酸酯∶催化剂=1∶0.01~0.02(mol/mol)。
本发明的目的第二方面是提供式Ⅰ所示的2-烷基-2-氰基戊酸酯在碱催化下水解制得2-烷基-2-氰基戊酸(Ⅱ):
R1选自苄基、C1~C5直链烷基或C3~C5支链烷基;R2选自甲基、乙基、丙基、丁基或异丙基。
本发明的目的第二方面是提供式Ⅰ所示的2-烷基-2-氰基戊酸酯在酸催化下水解和脱羧制得2-烷基戊酸(Ⅲ):
本发明的目的是提供化学结构式Ⅰ所示的2-烷基-2-氰基戊酸酯的制备方法:氰基乙酸甲酯与1-氯丙烷(含2-氯丙烷和1-氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2-烷基-2-氰基戊酸酯:
其中Ⅰ选自下列化合物:
本发明的目的是提供化学结构式Ⅰ所示的2-烷基-2-氰基戊酸酯的制备方法:氰基乙酸乙酯与1-氯丙烷(含2-氯丙烷和1-氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2-烷基-2-氰基戊酸酯:
其中Ⅰ选自下列化合物:
2-甲基戊酸(L)、2-丙基己酸(X)或2-异丙基戊酸(C)是氰基乙酸甲酯法(以氰基乙酸甲酯为原料制备丙戊酸的方法)制备丙戊酸P的工艺杂质。
2-乙基戊酸(B)、2-丙基己酸(X)或2-异丙基戊酸(C)是氰基乙酸乙酯法(以氰基乙酸乙酯为原料制备丙戊酸的方法)制备丙戊酸P的工艺杂质。
本发明与现有技术相比具有以下优点:
1.本发明中,采用氰基乙酸酯和1-氯丙烷的复合催化二烷基化方法:1-氯丙烷供应充足,来源丰富,且价廉;该关键性二丙基化反应完全,为最终产品高质量提供保障!
2.工艺中的中间体和产品纯度高,原料药生产成本低,质量好。具有很好的社会效益与经济效益。
3.确认了氰基乙酸甲酯法或氰基乙酸乙酯法制备丙戊酸P的工艺杂质的来源。
具体实施方式
下面结合实施例对本发明进行进一步的详细说明。
实施例1
2-氰基-2-丙戊酸甲酯的制备
29.73g(0.30mol)氰基乙酸甲酯、12.0mmol四丁基溴化铵、3.0mmolKI、91.21g(0.66mol)K2CO3、120ml DMF和58.91g(0.75mol)1-氯丙烷,85℃搅拌3.0h(TLC监测反应完成),反应毕,稍冷后过滤固体;有机相经旋蒸回收DMF;加水溶解固体,石油醚萃取,有机相与旋蒸回收DMF后的残液合并,水洗,蒸馏后得到淡黄色透明液体(2-氰基-2-丙戊酸甲酯)53.06g,收率96.50%(以氰基乙酸甲酯计);1H NMR(400MHz,DMSO-d6)δ:3.76(s,3H,OCH3),1.85–1.75(m,4H,CH2×2),1.52–1.38(m,2H,CH2),1.30–1.17(m,2H,CH2),0.91(t,J=7.2Hz,6H,CH3×2)。
同时副产下列化合物:
2-氰基-2-丙戊酸甲酯(HPLC,93%)和2-氰基-2-丙戊酸丙酯(HPLC,6%)的分子离子峰分别为[M+1]+=184,[M+1]+=212;石油醚过柱分离出2-氰基-2-丙基戊酸丙酯,1HNMR(400MHz,CDCl3)δ:4.16(t,J=6.8Hz,2H,OCH2),1.93–1.84(m,2H,CH2),
1.79–1.71(m,4H,CH2×2),1.65–1.55(m,2H,CH2),1.40–1.29(m,2H,CH2),0.98(t,J=7.2Hz,3H,CH3),0.96(t,J=7.2Hz,6H,CH3×2)。
实施例2
2-氰基-2-丙戊酸乙酯的制备
2.26g(20mmol)氰基乙酸乙酯、1mmolTBAC、0.5mmol KBr、6.08g(44mmol)K2CO3(200目)、8ml DMF和3.93g(50mmol)1-氯丙烷,80℃搅拌反应6h,过滤固体;有机相经旋蒸回收DMF;加水溶解固体,石油醚萃取,有机相与旋蒸回收DMF后的残液合并,水洗,蒸馏后得到淡黄色透明液体(2-氰基-2-丙戊酸乙酯)3.74g,收率94.9%(以氰基乙酸乙酯计)。1H NMR(400MHz,DMSO-d6)δ:4.22(q,J=7.2Hz,2H,OCH2),1.84–1.75(m,4H,CH2×2),1.52–1.39(m,2H,CH2),1.31–1.18(m,5H,CH2+CH3),0.91(t,J=7.2Hz,6H,CH3×2)。
同时副产下列化合物:
2-氰基-2-丙基戊酸丙酯,1H NMR(400MHz,CDCl3)δ:4.16(t,J=6.8Hz,2H,OCH2),1.93–1.84(m,2H,CH2),1.79–1.71(m,4H,CH2×2),1.65–1.55(m,2H,CH2),1.40–1.29(m,2H,CH2),0.98(t,J=7.2Hz,3H,CH3),0.96(t,J=7.2Hz,6H,CH3×2)。
实施例3
2-氰基-2-丙戊酸正丙酯的制备
0.30mol氰基乙酸丙酯、12.0mmol四丁基氯化铵、3.0mmolKI、91.21g(0.66mol)K2CO3、120mlDMF和58.91g(0.75mol)1-氯丙烷,85℃搅拌2.5h(TLC监测反应完成),反应毕,稍冷后过滤回收固体;有机相经旋蒸回收DMF;加水溶解固体,石油醚萃取,有机相与旋蒸回收DMF后的残液合并,水洗,蒸馏后制得淡黄色透明液体2-氰基-2-丙戊酸丙酯。分子离子峰分别为[M++1]=212;石油醚过柱分离出2-氰基-2-丙基戊酸丙酯,1HNMR(400MHz,CDCl3)δ:4.16(t,J=6.8Hz,2H,OCH2),1.93–1.84(m,2H,CH2),1.79–1.71(m,4H,CH2×2),1.65–1.55(m,2H,CH2),1.40–1.29(m,2H,CH2),0.98(t,J=7.2Hz,3H,CH3),0.96(t,J=7.2Hz,6H,CH3×2)。
同时副产下列化合物:
实施例4
2-氰基-2-丙戊酸的制备
29.73g(0.30mol)氰基乙酸甲酯、12.0mmol四丁基氯化铵、3.0mmolKI、91.21g(0.66mol)K2CO3、120mlDMF和58.91g(0.75mol)1-氯丙烷,85℃搅拌2.5h(TLC监测反应完成),反应毕,稍冷后过滤固体;有机相经旋蒸回收DMF;加水溶解固体,石油醚萃取,有机相与旋蒸回收DMF后的残液合并,水洗,蒸馏后得到淡黄色透明液体(2-氰基-2-丙戊酸酯),在淡黄色透明液体中,加150ml 15% KOH,升温水解3h,加浓盐酸中和,析出固体,干燥得白色固体48.69g 2-氰基-2-丙戊酸一水合物,收率86.7%(以氰基乙酸甲酯计),熔点49~50℃。1H NMR(400MHz,DMSO-d6)δ:13.76(s,1H,CO2H),
1.84–1.67(m,4H,CH2×2),1.54–1.41(m,2H,CH2),1.36–1.21(m,2H,CH2),0.92(t,J=7.2Hz,6H,CH3×2)。
实施例5
2-氰基-2-丙戊酸的制备
2.26g(20mmol)氰基乙酸乙酯、1mmol TBAC,6.08g(44mmol)K2CO3(100目),8ml DMF和0.5mmol溴化钾,3.93g(50mmol)1-氯丙烷,80℃搅拌反应6h,过滤固体;有机相经旋蒸回收DMF;加水溶解固体,石油醚萃取,有机相与旋蒸回收DMF后的残液合并,水洗,蒸馏后得到淡黄色透明液体,在残留的淡黄色透明液体(2-氰基-2-丙戊酸乙酯)中,加15ml 15%KOH,升温水解3h,加浓盐酸中和,析出固体,干燥得白色固体3.13g 2-氰基-2-丙戊酸一水合物,收率83.6%(以氰基乙酸乙酯计),熔点49~50℃。1HNMR(400MHz,DMSO-d6)δ:13.76(s,1H,CO2H),1.84–1.67(m,4H,CH2×2),1.54–1.41(m,2H,CH2),1.36–1.21(m,2H,CH2),0.92(t,J=7.2Hz,6H,CH3×2)。
实施例6
2-氰基-2-丙戊酸的制备
0.30mol氰基乙酸丙酯、12.0mmol四丁基氯化铵、3.0mmolKI、91.21g(0.66mol)K2CO3、120mlDMF和58.91g(0.75mol)1-氯丙烷,85℃搅拌2.5h(TLC监测反应完成),反应毕,稍冷后过滤固体;有机相经旋蒸回收DMF;加水溶解固体,石油醚萃取,有机相与旋蒸回收DMF后的残液合并,水洗,蒸馏后得到淡黄色透明液体,在残留的淡黄色透明液体(2-氰基-2-丙戊酸酯)中,加150ml 15% KOH,升温水解3h,加浓盐酸中和,析出固体,干燥得白色固体48.50g 2-氰基-2-丙戊酸一水合物,收率86.4%(以氰基乙酸丙酯计),熔点49~50℃。1HNMR(400MHz,DMSO-d6)δ:13.76(s,1H,CO2H),1.84–1.67(m,4H,CH2×2),1.54–1.41(m,2H,CH2),1.36–1.21(m,2H,CH2),0.92(t,J=7.2Hz,6H,CH3×2)。
实施例7
2-甲基戊酸(L)的制备
按上海青平药业有限公司[CN 202110336630.6]实施例1中描述的方法制备:在25.6g50%硫酸水溶液中,加入10g 2-氰基-2-甲基戊酸甲酯,升温至回流分水,缓慢分水,直到内温达到140℃分水结束,140℃反应15.0h以上,直到中间产物2-甲基戊酸酰胺反应完成;在反应液中加入10g水,分相,油相用水洗(10ml×3)至中性,油相加入14g 20%氢氧化钠水溶液,60℃水解5h。水解毕,静置分层;所得水相用二氯甲烷洗涤(10ml×3),分相,水相加入3.8g硫酸酸化pH=1,水洗涤(10ml×3),得到的油相加入无水硫酸钠干燥,过滤除盐,在60℃条件使用油泵减压浓缩至无气泡产生,得到3g 2-甲基戊酸L,纯度99%,收率39%。1H NMR(DMSO-d6,400MHz)δ:11.95(brs,1H,CO2H),2.37–2.21(m,1H,CH),1.62–1.42(m,1H,1/2CH2),1.38–1.16(m,3H,1/2CH2+CH2),1.03(d,J=7.0Hz,3H,CH3),0.85(t,J=7.2Hz,3H,CH3)。
实施例8
2-乙基戊酸(B)的制备
选择2-氰基-2-甲基戊酸乙酯,按实施例7操作方法制备2-乙基戊酸(B)。1H NMR(CDCl3,400MHz)δ:0.91(t,J=7.2Hz,3H,CH3),0.93(t,J=7.2Hz,3H,CH3),1.25–1.79(m,6H,CH2CH2+CH2),2.25–2.36(m,1H,CH),11.5(brs,1H,CO2H)。
实施例9
2-异丙基戊酸(C)的制备
按上海青平药业有限公司[CN 202110336630.6;中国医药工业杂志,2-异丙基戊酸的合成,2023,54(05):739-741]中描述的方法制备:在反应瓶中加入水(32.00g),缓慢加入浓硫酸(33.00g,0.33mol)和2-氰基-2-异丙基戊酸甲酯(25.00g,0.14mol),搅拌下回流,缓慢分水至内温达到150℃,保温反应20h。冷却,反应液中加入水(20mL),分相,有机相用水(15mL×3)洗涤,加入15%氢氧化钠溶液(31.00g),升温至60℃搅拌5h。降至室温,加入水(30.00g),用二氯甲烷(10mL×3)萃取,水相加入98%硫酸(7.82g)调至pH 1,分相,有机相用水(10mL×3)萃取,于60℃油泵减压浓缩至无馏出物,得浅黄色液体2-异丙基戊酸(C,7.00g,收率35%)。1H NMR(DMSO-d6,400MHz)δ:11.78(brs,1H,CO2H),2.16–2.11(m,1H,CH),1.92–1.86(m,1H,CH),1.64–1.45(m,2H,CH2),1.42–1.25(m,2H,CH2),0.97(d,J=7.2Hz,6H,CH3×2),0.91(t,J=7.2Hz,3H,CH3)。
实施例10
丙戊酸的制备
按(IN486MU2014A 2015-09-25)实施例1制备:将190g碎冰装入配备机械搅拌器的干燥2L四颈圆底烧瓶中,室温下搅拌10~15分钟,将硫酸(351g,98%)缓慢加入碎冰中并搅拌15分钟。反应混合物外部冷却至25℃~30℃,加入2-丙基-2-氰基戊酸(136g)和乙酸(200g)。在25℃~30℃下将四丁基硫酸氢铵(TBAHS,0.68g)加入到反应混合物中。反应混合物加热至110℃~130℃并根据需要将其搅拌15~16小时(通过GC监测)。反应毕,混合物冷至10℃~15℃,加入盐水溶液(8.0L)。通过酸碱处理,用甲苯萃取产物,得到粗制丙戊酸,为浅棕色至深棕色粘性液体。通过减压真空蒸馏纯化粗丙戊酸,产率85%~90%,纯度98.5%(GC)。1H NMR(400MHz,DMSO-d6)δ:11.99(s,1H,COOH),2.24–2.18(m,1H,CH),1.53–1.44(m,2H,CH2),1.39–1.34(m,2H,CH2),1.32–1.22(m,4H,CH2×2),0.86(t,J=7.2Hz,6H,CH3×2)。
实施例11
2-丙基基己酸(X)的制备
按实施例7操作方法制备2-丙基基己酸(X)。1H NMR(DMSO-d6,400MHz)δ:0.87(t,J=7.6Hz,6H,CH3+CH3),1.21–1.26(m,6H,CH2+CH2CH2),1.28–1.36(m,2H,CH2),1.41–1.53(m,2H,CH2),2.20–2.23(m,1H,CH),12.14(bs,1H,CO2H)。
在本说明书中,本发明已参照其特定的实施例作了描述。但是,很显然仍可以作出各种修改和变换而不背离本发明的精神和范围。因此,说明书应被认为是说明性的而非限制性的。
Claims (7)
1.一种式Ⅰ所示的2-烷基-2-氰基戊酸酯的制备方法:其特征在于氰基乙酸酯与1-氯丙烷(含2-氯丙烷和1-氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2-烷基-2-氰基戊酸酯:
其中,R1选自苄基、C1~C5直链烷基或C3~C5支链烷基;R2选自甲基、乙基、丙基、丁基或异丙基;
二烷基化的催化剂由催化剂R4NX和催化剂B组成;其中R=C1~C5直链烷基,X=Cl、Br或I;R4NX选自四丁基氯化铵、四丁基溴化铵、四丁基碘化铵、四丙基氯化铵、四丙基溴化铵、四丙基碘化铵、四乙基氯化铵、四乙基溴化铵、四乙基碘化铵、四甲基氯化铵、四甲基溴化铵或四甲基碘化铵;催化剂B选自KBr或KI;
二烷基化的溶剂选自THF、DMF、DMC、DMSO、乙腈、丙腈、丁腈、1,4-二氧六环、乙二醇二甲醚、乙二醇二乙醚、二乙二醇二甲醚、二乙二醇二乙醚;
K2CO3选自100目K2CO3、150目K2CO3、200目K2CO3、250目K2CO3、300目K2CO3或350目K2CO3;
二烷基化反应温度选自60℃~120℃;反应时间选自1.0h~12h;
二烷基化催化用量选自氰基乙酸酯∶催化剂=1∶0.01~0.02(mol/mol)。
2.如权利要求1所述的2-烷基-2-氰基戊酸酯的制备方法;其特征在于2-烷基-2-氰基戊酸酯在碱催化下水解制得2-烷基-2-氰基戊酸(Ⅱ):
R1和R2的定义如权利要求1所述。
3.如权利要求1所述的2-烷基-2-氰基戊酸酯的制备方法,其特征在于2-烷基-2-氰基戊酸酯在酸催化下水解和脱羧制得2-烷基戊酸(Ⅲ):
R1和R2的定义如权利要求1所述。
4.如权利要求1所述的2-烷基-2-氰基戊酸酯的制备方法;其特征在于式Ⅰ所示的2-烷基-2-氰基戊酸酯的制备方法:选择氰基乙酸甲酯与1-氯丙烷(含2-氯丙烷和1-氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2-烷基-2-氰基戊酸酯:
其中Ⅰ选自下列化合物:
二烷基化反应的催化剂、溶剂和碱的定义如权利要求1所述。
5.如权利要求1所述的2-烷基-2-氰基戊酸酯的制备方法;其特征在于式Ⅰ所示的2-烷基-2-氰基戊酸酯的制备方法:选择氰基乙酸乙酯与1-氯丙烷(含2-氯丙烷和1-氯丁烷),在K2CO3作用下,复合催化二烷基化制得Ⅰ所示的2-烷基-2-氰基戊酸酯:
其中Ⅰ选自下列化合物:
二烷基化反应的催化剂、溶剂和碱的定义如权利要求1所述。
6.如权利要求3所述的制备方法,其特征在于其中2-烷基戊酸(Ⅲ)选自下列化合物:
2-甲基戊酸(L)、2-丙基己酸(X)或2-异丙基戊酸(C)是氰基乙酸甲酯法制备丙戊酸P的工艺杂质。
7.如权利要求3所述的制备方法,其特征在于其中2-烷基戊酸(Ⅲ)选自下列化合物:
2-乙基戊酸(B)、2-丙基己酸(X)或2-异丙基戊酸(C)是氰基乙酸乙酯法制备丙戊酸P的工艺杂质。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311398742.XA CN117430527A (zh) | 2023-10-26 | 2023-10-26 | 一种2-烷基-2-氰基戊酸酯的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311398742.XA CN117430527A (zh) | 2023-10-26 | 2023-10-26 | 一种2-烷基-2-氰基戊酸酯的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117430527A true CN117430527A (zh) | 2024-01-23 |
Family
ID=89552846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311398742.XA Pending CN117430527A (zh) | 2023-10-26 | 2023-10-26 | 一种2-烷基-2-氰基戊酸酯的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117430527A (zh) |
-
2023
- 2023-10-26 CN CN202311398742.XA patent/CN117430527A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114763319B (zh) | 一种联产丙戊酰胺和丙戊酸钠的方法 | |
EP2133322A1 (en) | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
CN102627573A (zh) | 5-氨基酮戊酸盐酸盐的合成方法 | |
CN110790721B (zh) | 头孢他啶侧链酸乙酯的合成方法 | |
CA2889650C (en) | Process and intermediates for preparing lacosamide | |
KR101653025B1 (ko) | 2-아미노-4-트리플루오로메틸피리딘류의 제조 방법 | |
JP5588130B2 (ja) | メチレンビス(ベンゾトリアゾリルフェノール)化合物の製造方法 | |
CN108623455B (zh) | 一种抗心衰药物的中间体 | |
KR101135088B1 (ko) | 1,3-프로펜설톤의 제조방법 | |
CN114790151B (zh) | 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法 | |
CN114763328B (zh) | 一种2-氰基-2-丙戊酸的制备方法与应用 | |
CN117430527A (zh) | 一种2-烷基-2-氰基戊酸酯的制备方法 | |
JP7471306B2 (ja) | 4-(2,2,3,3-テトラフルオロプロピル)モルホリンを製造する方法 | |
JP6260385B2 (ja) | 2−ヒドロキシメチル−2,3−ジヒドロ−チエノ[3,4−b][1,4]ジオキシン−5,7−ジカルボン酸ジアルキルエステルの製造方法 | |
JP2023532362A (ja) | フェニルイソオキサゾリン系化合物の製造方法 | |
CN109574866B (zh) | 一种2,6-二甲基苯胺类长链化合物的制备方法 | |
CN116768697B (zh) | 一种氯丙烷作烷化剂制备二丙基丙二酸的方法与应用 | |
EP2474536B1 (en) | Process for preparation of pyrimidinylacetonitrile derivatives and intermediates for synthesis thereof | |
WO2004087640A1 (en) | Process for the manufacture of n-alkoxalyl-alaninates | |
JP2020079247A (ja) | シクロブタンテトラカルボン酸及びその無水物の製造方法 | |
US5874466A (en) | Process for the manufacture of acetonylbenzamides | |
CN116730832B (zh) | 一种2-丙基己酸的制备方法 | |
CN115636764B (zh) | 一种苯甲酰胺化合物的合成方法 | |
CN116621732A (zh) | 一种2-氰基-2-丙戊酸酯及其制备方法与应用 | |
CN117430509A (zh) | 一种2-烷基-2-丙基丙二酸二酯的制备与水解方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |